Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
10 avr. 2024 07h30 HE
|
Cytokinetics, Incorporated
Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional Analyses from SEQUOIA-HCM Assess Effect of Aficamten...
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session
05 avr. 2024 07h30 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced additional 48-week data from FOREST-HCM (Follow-up, Open-Label, Research...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 avr. 2024 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 29, 2024 it granted stock options to purchase an aggregate of...
Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
01 avr. 2024 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to...
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session
25 mars 2024 08h15 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the American College of Cardiology 73rd Annual...
Cytokinetics to Participate in March Investor Conferences
04 mars 2024 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 mars 2024 16h00 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 29, 2024 it granted stock options to purchase an aggregate...
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
29 févr. 2024 07h30 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is joining the European Organisation for Rare Diseases (EURORDIS) and...
Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials
28 févr. 2024 07h30 HE
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., and ALBANY, Ga., and WASHINGTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), together with The Mended Hearts, Inc. and WomenHeart: The...
Cytokinetics Reports Fourth Quarter 2023 Financial Results
27 févr. 2024 16h00 HE
|
Cytokinetics, Incorporated
Topline Results from SEQUOIA-HCM Announced in DecemberShowed Statistically Significant and Clinically Meaningful Increasein Primary Efficacy Endpoint and Improvements in All Secondary Endpoints ...